BHIVA Autumn Conference
4–5 October 2018
QEII Centre, London

Preceded by
BHIVA Hepatology Highlights for the Healthcare Specialist
in collaboration with the
British Viral Hepatitis Group (BVHG)
Wednesday 3 October 2018

Meeting Sponsors 2018:

www.bhiva.org
#BHIVA2018

Follow us on social media

Download the BHVA Conferences App

BHIVA Major Sponsors 2018
ART-naïve patients achieved VL <50 copies/mL, comparable to 88.4% in control*1
The high genetic barrier to resistance of DRV1,2
No serious CNS or psychiatric AEs related to Symtuza® in AMBER or EMERALD§1,2
Virologic rebound† in ART-experienced patients, comparable to 2.1% in control†2
Few SAEs and AE-related discontinuations across groups1,2
Renal and bone findings consistent with the known effects of TAF and cobicistat1,2

91.4% (331/362)
2.5% (19/763)

SINGLE PILL SUSTAINED EFFICACY AT 48 WEEKS1,2

Prescribing information can be found at: https://www.janssen-pi.co.uk/en/product-information/29

*DRV/C + FTC/TDF. †Confirmed VL ≥50 copies/mL or premature discontinuations with last VL ≥50 copies/mL. ‡Continued treatment with bPI + FTC/TDF. §In EMERALD, one Symtuza® patient discontinued due to headache and one due to a psychiatric event; there were no CNS/psychiatric AEs-related discontinuations in the control arm. AE: adverse event; ART: antiretroviral therapy; CNS: central nervous system; DRV: darunavir; SAE: serious adverse event; TAF: tenofovir alafenamide; VL: viral load.


Adverse events should be reported. ▼ This medicinal product is subject to additional monitoring and it is therefore important to report any suspected adverse events related to this medicinal product. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Janssen-Cilag Limited on 01494 567447 or at dsafety@its.jnj.com.

Symtuza® is indicated for the treatment of HIV-1 infection in adults and adolescents (aged 12 years and older with body weight at least 40 kg). Genotypic testing should guide the use of Symtuza®. Please see the Symtuza® Summary of Product Characteristics for further advice.

Date of preparation: September 2018. PHGB/SYM/0918/0001
Dear Colleague

Welcome to the BHIVA Autumn Conference, which this year will be preceded by the BHIVA Hepatology Highlights for the Healthcare Specialist.

Again, both events are held at the prestigious QEII Centre, in the heart of London.

I would like to thank Dr Laura Waters (Chair of the Conferences Subcommittee), Mr Paul Clift and Dr Ranjababu Kulasegaram Reeves (Conference Local Hosts) and all the members of the Conferences Subcommittee, for their efforts in preparing an excellent programme for this conference.

The conference sessions will cover a wide range of important topics relevant to HIV. Please refer to the programme pages for a full schedule of topics and timings.

The BHIVA Annual General Meeting will be held on Friday 5 October prior to lunch. I would encourage all BHIVA members to attend this meeting, as it provides a forum to present any points they may have to the BHIVA Officers and members of the Executive Committee.

Finally, we would like to thank our sponsors for their continued support of the Association, which assists greatly with covering some of the costs incurred in organising this conference.

We very much hope you enjoy the programme and find it relevant to both your educational and practical needs.

Professor Chloe Orkin
Chair, British HIV Association
### BHIVA COMMITTEES

#### EXECUTIVE COMMITTEE

<table>
<thead>
<tr>
<th>OFFICERS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chair</strong></td>
</tr>
<tr>
<td>Prof C Orkin</td>
</tr>
<tr>
<td><strong>Vice Chair</strong></td>
</tr>
<tr>
<td>Prof C Leen</td>
</tr>
<tr>
<td><strong>Honorary Secretary</strong></td>
</tr>
<tr>
<td>Dr A Sullivan</td>
</tr>
<tr>
<td><strong>Honorary Treasurer</strong></td>
</tr>
<tr>
<td>Dr D Churchill</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MEMBERS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prof B Angus</td>
</tr>
<tr>
<td>Dr F Burns</td>
</tr>
<tr>
<td>Dr D Chadwick</td>
</tr>
<tr>
<td>Dr M Chaponda</td>
</tr>
<tr>
<td>Mr P Clift</td>
</tr>
<tr>
<td>Dr R Dhairyawan</td>
</tr>
<tr>
<td>Prof B Gazzard CBE</td>
</tr>
<tr>
<td>Dr Y Gilleece</td>
</tr>
<tr>
<td>Dr N Gupta</td>
</tr>
<tr>
<td>Dr R Kulasegaram</td>
</tr>
<tr>
<td>Dr N Larbalestier</td>
</tr>
<tr>
<td>Dr N Mackie</td>
</tr>
<tr>
<td>Dr I Reeves</td>
</tr>
<tr>
<td>Prof C Sabin</td>
</tr>
<tr>
<td>Dr S Taylor</td>
</tr>
<tr>
<td>Dr L Waters</td>
</tr>
</tbody>
</table>

#### CONFERENCES SUBCOMMITTEE

<p>| |</p>
<table>
<thead>
<tr>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chair and BHIVA Executive Committee member</strong></td>
</tr>
<tr>
<td>Dr L Waters</td>
</tr>
<tr>
<td><strong>Vice Chair, BHIVA Executive Committee member</strong></td>
</tr>
<tr>
<td>Dr I Reeves</td>
</tr>
<tr>
<td><strong>BHIVA Executive Committee member</strong></td>
</tr>
<tr>
<td>Dr M Chaponda</td>
</tr>
<tr>
<td><strong>BHIVA Executive Committee member</strong></td>
</tr>
<tr>
<td>Dr D Churchill</td>
</tr>
<tr>
<td><strong>BHIVA Executive Committee member</strong></td>
</tr>
<tr>
<td>Mr P Clift</td>
</tr>
<tr>
<td>Prof B Gazzard CBE</td>
</tr>
<tr>
<td><strong>BHIVA Executive Committee member and Joint Local Host</strong></td>
</tr>
<tr>
<td>Dr R Kulasegaram</td>
</tr>
<tr>
<td><strong>BHIVA Executive Committee member</strong></td>
</tr>
<tr>
<td>Dr N Mackie</td>
</tr>
<tr>
<td><strong>BHIVA Executive Committee member</strong></td>
</tr>
<tr>
<td>Prof C Orkin</td>
</tr>
<tr>
<td><strong>BHIVA Executive Committee member</strong></td>
</tr>
<tr>
<td>Prof C Sabin</td>
</tr>
<tr>
<td>Mrs S Morris</td>
</tr>
<tr>
<td>Dr E Wilkins</td>
</tr>
</tbody>
</table>
WEDNESDAY 3 OCTOBER 2018

Gielgud, 2nd Floor, QEII Centre

Hepatology Highlights for the Healthcare Specialist in collaboration with the British Viral Hepatitis Group (BVHG)

Meeting Sponsors 2018

1800–2000  Registration and exhibition open

1830–1835  Welcome Address
Professor David Mutimer
University Hospitals Birmingham NHS Foundation Trust

1835–1905  Micro elimination: HIV, HCV in the UK
Professor Graham Cooke
Imperial College Healthcare NHS Trust, London

1905–1935  HCV resistance testing in clinical practice
Dr Daniel Bradshaw
Public Health England

1935–2005  New targets and therapies in hepatitis B
Dr Douglas Macdonald
Royal Free London NHS Foundation Trust

2005–2025  Panel discussion

2025–2030  Close
Professor David Mutimer
University Hospitals Birmingham NHS Foundation Trust

THURSDAY 4 OCTOBER 2018

All sessions will be held in the Mountbatten, 6th Floor, QEII Centre unless otherwise stated

0830–1830  Registration and exhibition open

0855–0900  Welcome Address by the Chair of BHIVA
Professor Chloe Orkin
Barts Health NHS Trust, London

0900–0930  BHIVA Audit Session
Chair: Dr Ann Sullivan
Chelsea and Westminster Hospital, London
Over 50s monitoring audit
Dr Nadia Ekong
Leeds General Infirmary
Late diagnosis review process
Dr David Chadwick
James Cook University Hospital, Middlesbrough

0930–1030  MSD Satellite Symposium (see page 10 for further information)

1030–1100  Morning coffee
THURSDAY 4 OCTOBER 2018

1100–1200  BHIVA Guidelines Session
Chairs: Dr Jasmini Alagaratnam
Imperial College Healthcare NHS Trust, London
Dr Yvonne Gilleece
Brighton and Sussex University Hospital NHS Trust
Dr Adrian Palfreeman
Leicester Royal Infirmary

BHIVA/BASHH guidelines on the use of HIV pre-exposure prophylaxis (PrEP)
Professor Alison Rodger
Royal Free and University College Medical School, London

BHIVA guidelines for the management of tuberculosis in adults living with HIV 2018
Dr Margherita Bracchi
Chelsea and Westminster Hospital, London

1200–1230  BHIVA Foundation Lecture
Chair: Professor Chloe Orkin
Barts Health NHS Trust, London

Vaginal microbiome
Professor Janneke van de Wijgert
University of Liverpool

1230–1415 Lunch and Lunchtime Workshops

1235–1320  BHIVA Lunchtime Workshop: Clinico-pathological case presentation workshop
Facilitators: Professor Mark Bower
Chelsea and Westminster Hospital, London
Dr Ula Mahadeva
Guy’s and St Thomas’ NHS Foundation Trust

If the problem is more than just skin deep, don’t make a rash decision
Dr Laurence Dufaur
Barts Health NHS Trust, London

No body expects the Spanish Inquisition
Dr Tamara Elliott
Imperial College Healthcare NHS Trust, London

1315–1415  Gilead Sciences Lunchtime Workshop
Abbey, Fourth Floor (see page 10 for further information)

1415–1515  BHIVA Plenary Session: HIV and the lung
Chairs: Dr Rageshri Dhairyawan
Barts Health NHS Trust, London
Dr Nick Larbalestier
Guy’s and St Thomas’ NHS Foundation Trust, London

Chronic obstructive pulmonary disease, interstitial lung disease and cancer
Dr Marc Lipman
Royal Free London NHS Foundation Trust

Challenges faced when diagnosing, treating and eliminating TB
Dr Alberto Garcia-Basteiro
Manhiça Health Research Centre (CISM), Mozambique and Barcelona Institute for Global Health, Spain

1515–1615  ViiV Healthcare Satellite Symposium (see page 10 for further information)

1615–1645  Afternoon tea
THURSDAY 4 OCTOBER 2018

1645–1730  BHIVA/UKCAB Community Symposium

Chairs: Mr Paul Clift
UK Community Advisory Board

Dr Matthew Page
Heart of England NHS Foundation Trust, Birmingham

What is the future of local clinical and community HIV services?
Ms Juliet Reid
Centre for All Families Positive Health

Mr George Valiotis
HIV Scotland

Ms Ceri Dunstan
Terrence Higgins Trust

Mr Rob Coster
NHS England

1730–1800  BHIVA Invited Lecture 1

Chair: Dr Iain Reeves
Homerton University Hospital, London

UK Civil Aviation Authority guidance on aeromedical certification for HIV-positive applicants
Dr Duncan Churchill
Brighton and Sussex University Hospitals NHS Trust

Dr Ewan Hutchison
UK Civil Aviation Authority

Mr Anthony Smith
Pilot

1800–1830  BHIVA Invited Lecture 2

Chairs: Dr Nicola Mackie
Imperial College Healthcare NHS Trust, London

Dr Laura Waters
Mortimer Market Centre, London

Addressing issues of parenthood and reproductive health with gay and bisexual men as part of HIV care: findings from the MAIL study
Dr Robert Pralat
University of Cambridge

Surrogacy challenges for people with HIV: the legal and regulatory aspects of surrogacy and sperm/egg donation
Ms Natalie Gamble
Natalie Gamble Associates

1830–1845  CHIVA Performance

Life Growing Up
This is spoken word/storytelling performance created with young people who have grown up living with HIV, through participation in the arts engagement programme delivered by CHIVA (UK).

1845–1930  Drinks Reception
Cambridge and Windsor, 5th Floor
FRIDAY 5 OCTOBER 2018

All sessions will be held in the Mountbatten, 6th Floor, QEII Centre unless otherwise stated

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>0800–1440</td>
<td>Registration desk and exhibition open</td>
</tr>
</tbody>
</table>
| 0815–0900 | **SWIFT: caring for women living with HIV – models, standards and guidelines in 2018**  
Dr Yvonne Gilleece  
Brighton and Sussex University Hospitals NHS Trust  
Dr Kate Nambiar  
Brighton and Sussex University Hospitals NHS Trust |
| 0900–1030 | **BHIVA Best Practice Management Session:**  
‘I keep forgetting things’: what to ask, when to worry, what to send and who to refer to  
Chairs: Dr Tristan Barber  
Royal Free London NHS Foundation Trust  
Dr Fiona Burns  
University College London  
Dementia diagnosis and classification, when to lumbar puncture and what to send  
Dr Paul Holmes  
Guy’s and St Thomas’ NHS Foundation Trust  
**CSF escape: the consensus, definition and management approaches**  
Professor Alan Winston  
Imperial College Healthcare NHS Trust, London  
**Psychological management: practical approaches to intervention and support**  
Dr Shimu Khamlichi  
Royal Free London NHS Foundation Trust  
Panel discussion |
| 1030–1040 | **BHIVA Awards Ceremony**  
Professor Caroline Sabin  
University College London |
| 1040–1110 | Morning coffee                                                          |
| 1110–1210 | **Gilead Sciences Satellite Symposium** (see page 10 for further information) |
| 1210–1240 | **CHIVA Plenary Lecture**  
Chair: Dr Amanda Williams  
North West London Hospitals NHS Trust  
**HIV/hepatitis co-infection and prevention of mother-to-child transmission**  
Dr Claire Thorne  
UCL Great Ormond Street Institute of Child Health |
| 1240–1310 | **BHIVA Gazzard Lectureship in HIV Medicine**  
Chair: Professor Brian Gazzard  
Chelsea and Westminster Hospital, London  
**How HIV alters macrophage responses to bacteria and other diseases**  
Professor David Dockrell  
University of Edinburgh |
| 1310–1330 | **BHIVA Annual General Meeting** |
| 1310–1440 | Lunch and Lunchtime Workshops                                           |
**Final Programme**

**FRIDAY 5 OCTOBER 2018**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>1335–1420</td>
<td><strong>BHIVA Lunchtime Workshop</strong></td>
</tr>
<tr>
<td></td>
<td>Chairs: Dr Nadi Gupta</td>
</tr>
<tr>
<td></td>
<td><em>Rotherham NHS Foundation Trust</em></td>
</tr>
<tr>
<td></td>
<td>Professor Brian Angus</td>
</tr>
<tr>
<td></td>
<td><em>University of Oxford</em></td>
</tr>
<tr>
<td></td>
<td><strong>HIV and disability: a clinical update</strong></td>
</tr>
<tr>
<td></td>
<td>Mr Darren Brown</td>
</tr>
<tr>
<td></td>
<td><em>Chelsea and Westminster Hospital, London</em></td>
</tr>
<tr>
<td></td>
<td>Mr Colin Corbett</td>
</tr>
<tr>
<td></td>
<td><em>Chelsea and Westminster Hospital, London</em></td>
</tr>
<tr>
<td></td>
<td>Professor Richard Harding</td>
</tr>
<tr>
<td></td>
<td><em>King’s College London</em></td>
</tr>
<tr>
<td></td>
<td>Dr Kelly O’Brien</td>
</tr>
<tr>
<td></td>
<td><em>University of Toronto, Canada</em></td>
</tr>
<tr>
<td>1440–1510</td>
<td><strong>BHIVA Invited Lecture 3</strong></td>
</tr>
<tr>
<td></td>
<td>Chairs: Dr Ranjababu Kulesagaram</td>
</tr>
<tr>
<td></td>
<td><em>Guy’s and St Thomas’ NHS Foundation Trust</em></td>
</tr>
<tr>
<td></td>
<td>Professor Clifford Leen</td>
</tr>
<tr>
<td></td>
<td><em>NHS Lothian, Edinburgh</em></td>
</tr>
<tr>
<td></td>
<td><strong>Dispelling the myths around HIV and ageing and changing the causes of mortality</strong></td>
</tr>
<tr>
<td></td>
<td>Professor Caroline Sabin</td>
</tr>
<tr>
<td></td>
<td><em>University College London</em></td>
</tr>
<tr>
<td>1510–1540</td>
<td><strong>BHIVA Invited Lecture 4</strong></td>
</tr>
<tr>
<td></td>
<td>Chairs: Dr Ranjababu Kulesagaram</td>
</tr>
<tr>
<td></td>
<td><em>Guy’s and St Thomas’ NHS Foundation Trust</em></td>
</tr>
<tr>
<td></td>
<td>Professor Clifford Leen</td>
</tr>
<tr>
<td></td>
<td><em>NHS Lothian, Edinburgh</em></td>
</tr>
<tr>
<td></td>
<td><strong>The gut microbiome</strong></td>
</tr>
<tr>
<td></td>
<td>Dr Caroline Le Roy</td>
</tr>
<tr>
<td></td>
<td><em>Kings College London</em></td>
</tr>
<tr>
<td>1540–1640</td>
<td><strong>BHIVA Clinical and Ethical Conundrums Session</strong></td>
</tr>
<tr>
<td></td>
<td>Chairs: Dr Mas Chaponda</td>
</tr>
<tr>
<td></td>
<td><em>University of Liverpool</em></td>
</tr>
<tr>
<td></td>
<td>Dr Hannah Pintilie</td>
</tr>
<tr>
<td></td>
<td><em>Imperial College Healthcare NHS Trust, London</em></td>
</tr>
<tr>
<td></td>
<td>Dr Steve Taylor</td>
</tr>
<tr>
<td></td>
<td><em>Heart of England NHS Foundation Trust, Birmingham</em></td>
</tr>
<tr>
<td></td>
<td><strong>Bone marrow transplants</strong></td>
</tr>
<tr>
<td></td>
<td>Dr Ian Gabriel</td>
</tr>
<tr>
<td></td>
<td><em>Chelsea and Westminster Hospital, London</em></td>
</tr>
<tr>
<td></td>
<td><strong>Novel drug interactions</strong></td>
</tr>
<tr>
<td></td>
<td>Professor Saye Khoo</td>
</tr>
<tr>
<td></td>
<td><em>University of Liverpool</em></td>
</tr>
<tr>
<td></td>
<td><strong>Disclosure of HIV in an era of U=U: should you always tell your partners?</strong></td>
</tr>
<tr>
<td></td>
<td>Dr Mary Poulton</td>
</tr>
<tr>
<td></td>
<td><em>King’s College Hospital NHS Foundation Trust, London</em></td>
</tr>
<tr>
<td>1640</td>
<td><strong>Close by the Chair of the British HIV Association</strong></td>
</tr>
<tr>
<td></td>
<td>Professor Chloe Orkin</td>
</tr>
<tr>
<td></td>
<td><em>Barts Health NHS Trust, London</em></td>
</tr>
</tbody>
</table>
PROGRAMME OF SATELLITE SYMPOSIA
AND SPONSORS’ LUNCHTIME WORKSHOPS

THURSDAY 4 OCTOBER

0930–1030

**MSD Satellite Symposium**

Women Living with HIV: Are we up to the challenge?

*Chair:* Dr Yvonne Gilleece  
*Brighton and Sussex University Hospitals NHS Trust*

*Speakers:* Dr Subathira Dakshina  
*Mortimer Market Centre, London*  
Dr Sonia Raffe  
*Brighton and Sussex University Hospitals NHS Trust*

1315–1415

**Gilead Sciences Lunchtime Workshop (Abbey, Fourth Floor)**

HIV and Integrated Care - Can STPs deliver

*Chair:* Professor Jane Anderson  
*Homerton University Hospital, London*

*Speakers:* Dr Yusef Azad  
*National AIDS Trust*  
Mr Alex Baylis  
*Kings Fund*  
Ms Eleanor Roaf  
*Trafford MBC*  
Ms Julie Lowe  
*South East London Sustainability and Transformation Partnership*

1515–1615

**ViiV Healthcare Satellite Symposium**

Could Less be More?

*Chair:* Dr Mike Youle  
*Royal Free London NHS Foundation Trust*

*Speakers:* Dr Laura Waters  
*Mortimer Market Centre, London*  
Dr Nicola Mackie  
*Imperial College Healthcare NHS Trust, London*  
Dr Tristan Barber  
*Royal Free London NHS Foundation Trust*

FRIDAY 5 OCTOBER

1110–1210

**Gilead Sciences Satellite Symposium**

Two-drug combinations and triple therapy: exploring data gaps

*Chair:* Professor Chloe Orkin  
*Barts Health NHS Trust, London*

*Speakers:* Professor Ravindra Gupta  
*University College London*  
Professor Pierre Corbeau  
*University of Montpellier, France*
BHIVA Autumn Conference: 4–5 October 2018
The registration fee gives access to the scientific sessions of the BHIVA Autumn Conference, including satellite symposia. All refreshments and lunches throughout the conference are included in the registration fee.

Sponsors’ Lunchtime Workshops
Places are limited and will be restricted to 80 delegates per workshop. Places will be available on site, on a first-come, first-served basis, at the door of the lunchtime workshop. Doors will open 15 minutes prior to the start of each workshop. Each workshop will begin promptly at the time stated in the programmes.

Prizes and awards

The Don Jeffries BHIVA Research Award
BHIVA created this award in honour of the late Professor Don Jeffries. This will be awarded for the highest-scoring application, as judged by the BHIVA Research Awards Judging Panel, from the applications submitted for the 2018 BHIVA Research Awards. The award will be presented in the lecture theatre as part of the morning sessions on Friday 5 October 2018.

BHIVA Best Clinico-pathological Case Presentation:
A prize will be awarded to the presenter of the best case for each of the above workshops. The prize will be presented during the prizes and awards ceremony on the morning of Friday 5 October 2018.

Continuing Professional Development (CPD)
Medical staff in career grade posts who are enrolled with one of the Royal Medical Colleges for Continuing Professional Development will receive CPD credit at the rate of one CPD credit per conference hour (exclusive of travel, refreshments, social events and satellite symposia). The conference will be allocated a maximum of 6 CPD credits per conference day.

<table>
<thead>
<tr>
<th>CPD Accreditation: Credits attributed and unique reference number</th>
</tr>
</thead>
<tbody>
<tr>
<td>BHIVA Autumn</td>
</tr>
<tr>
<td>Hepatology Highlights for the Healthcare Specialist.</td>
</tr>
<tr>
<td>In collaboration with BVHG.</td>
</tr>
</tbody>
</table>

BHIVA Community Registration
BHIVA has supported free registrations for over 40 community representatives to attend the conference.

BHIVA Registration Scholarships
BHIVA Registration Scholarships have been made available to 6 delegates, who are doctors and who are retired, not working or employed in a part-time or equivalent capacity, or who are students involved in full-time undergraduate or post-graduate work. The scholarships cover the conference registration fee.

Cloakroom
A staffed cloakroom is available at the QEII Centre. All belongings are left at the owner’s risk. The QEII Centre and the British HIV Association do not accept responsibility for the loss of, or damage to, delegates’ personal property stored in the cloakroom areas.

WiFi Connectivity
Free WiFi access will be available at the conference venue.

Social Media
Follow BHIVA on social media:

The default social media policy for the conference is that communication of presentations is acceptable including real-time communication on social media that supports knowledge sharing with the public and scientific community. Presenters need to make sure that any patient data is anonymised. If presenters discuss cases, they must ensure they adhere to professional guidance on consent (GMC or NMC). Presenters who choose to explicitly state that they do not want aspects of their presentation copied and displayed on social media will need to include the following symbol on their introductory slide or poster.
BHIVA Conferences App
BHIVA have developed a conference app which is downloadable from App Store for iPhone users or Playstore for Android devices. The app will provide users with the following facilities:

- Text the Chair (note all questions will be moderated)
- Voting during sessions
- Information on the conference programme speakers, sponsors and exhibitors
- Ability to complete the Conference Evaluation Questionnaire via the app

Conference venue

**QEII Centre**

Broad Sanctuary • Westminster • London SW1P 3EE  
☎ +44 (0)20 7222 5000 • www.qeiicc.co.uk

The conference venue is a short walk from Westminster or St James’s Park underground stations. Please see the map for the location of these stations in relation to the QEII Centre.

Westminster and St James’s Park underground stations are easily accessible from King's Cross, St Pancras (Eurostar) and Victoria main-line rail stations and can be accessed by the Jubilee line or the Circle and District lines. The journey from these main-line stations to Westminster or St James’s Park underground stations takes approximately 10 minutes.

There are also good links to the city centre from both Heathrow and Gatwick airports. Journeys by either Heathrow or Gatwick Express take about 1 hour.

There are four car parks near to the conference venue. For further information please visit www.ncp.co.uk

Please note that the conference venue is located within the London Congestion Charge Zone.
Autumn Exhibition Floorplan Cambridge and Windsor, Fifth Floor

EXHIBITORS

1. Kora Healthcare  
2. ViiV Healthcare UK  
3. Janssen  
4. National HIV Nurses Association  
5. Terrence Higgins Trust  
6. UK Community Advisory Board / HIV i-Base  
7. Positively UK  
8. Positive East  
9. HIV Trainees Club  
10. Roche Diagnostics  
11. Saving Lives  
12. National AIDS Trust  
13. The Sophia Forum  
14. Children’s HIV Association  
15. Mildmay  
16. cliniQ  
17. Centre for All Families Positive Health  
18. NAM  
19. MSD  
20. Gilead Sciences
PLENARY SPEAKER BIOGRAPHIES

**Professor Mark Bower** is a consultant medical oncologist at Chelsea and Westminster Hospital and professor at Imperial College who specialises in the treatment of AIDS-related malignancies. He has developed one of the largest centres for the management of these tumours in Europe, receiving referrals from throughout the UK and has cared for over 3000 patients with HIV-associated cancers. His clinical research covers the epidemiology, aetiology, pathogenesis and management of these tumours. He is a scientific advisor to UNAIDS.

**Dr Margherita Bracchi** specialised in infectious diseases at the University of Turin (Italy) in July 2013. Between 2013 and 2016 she worked as clinical trial physician at St Stephen’s AIDS Trust, and as trust grade at Chelsea and Westminster Hospital, looking after patients with HIV, with a specialist interest in those with HIV and TB. She was appointed consultant in HIV/infectious diseases at Chelsea and Westminster Hospital in 2017, where she looks after inpatients and outpatients with HIV and TB. She is a member of the BHIVA guidelines on the management of HIV and TB writing group and the current Young Investigator for the EACS ART panel.

**Dr Daniel Bradshaw** trained in GU medicine at Chelsea and Westminster Hospital and in viral hepatitis at the Kirby Institute, Sydney. He is currently a senior clinical fellow in virology at Public Health England, where his main role has been to support the launch of the HCV next generation sequencing service. He chairs the PHE HCV Resistance Group, which aims to provide clinical guidance and develop scientific proposals in the field of HCV resistance.

**Mr Darren Brown** is a clinical physiotherapist specialising in HIV, oncology and palliative care and leads the HIV physiotherapy service providing both inpatient and outpatient physiotherapy interventions for adults living with HIV at Chelsea and Westminster Hospital NHS Foundation Trust. His clinical and research interests focus on disability experienced by people living with HIV and effectiveness of rehabilitation intervention for people living with HIV. He created and developed the Kobler Rehabilitation Class, a group rehabilitation intervention for adults living with HIV, providing individualised exercise and HIV-specific education, and the mHealth app BeYou+, which supports self-management strategies among people living with HIV. Darren is currently studying for an NIHR-awarded masters of clinical research at St Georges University, London and is the HIV/AIDS special interest coordinator of WCPT Network IPT-HOPE, WCPT Congress programme committee member for Geneva, vice-chair of the UK Rehabilitation in HIV Association, and member of Canada-International HIV Rehabilitation Research collaborative.

**Dr David Chadwick** is an infectious diseases physician in Middlesbrough who has worked in HIV medicine for over 20 years, with research interests in HIV and viral hepatitis co-infection in Africa and HIV testing in the UK. He is currently leading the BHIVA guidelines on the management of opportunistic infections writing group and chairs the Audit and Standards subcommittee, in which role he has developed an interest in late HIV diagnosis and strategies to reduce late diagnosis.

**Dr Duncan Churchill** has been a consultant at the Royal Sussex County Hospital in Brighton since 1999. After studying at Oxford University and the Middlesex Hospital Medical School, he trained in HIV medicine at the Middlesex and St Mary’s Hospitals. He is currently honorary treasurer of the British HIV Association (BHIVA), past chair of the BHIVA guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy writing group, and is deputy convenor of the diploma in HIV medicine examination at the Worshipful Society of Apothecaries.

**Mr Paul Clift** is the HIV patients’ representative and peer support worker at King’s College Hospital. He is a member of the Core Advisory Group of the HIV Psychosocial Network and is a member of the steering committees of UK Community Advisory Board (UK-CAB) and of its European counterpart, ECAB. Paul was a member of the Clinical Reference Group for HIV from its inception in 2011 until March 2016 and was a member of the PrEP Policy writing group for NHS England from August 2014 to March 2016. He is currently a member of the Community Advisory Group of the PrEP IMPACT trial.

**Dr Graham Cooke** is an NIHR research professor based in infectious diseases at Imperial College London and chairs the BHIVA expert advisory group on hepatitis. His research interests include the use of new DAA therapies for hepatitis C and access to treatment in low-income settings. He leads the STOPHCV-1 strategic trial in the UK and the SEARCH consortium in SE Asia and is co-chair of the WHO Essential Medicines List.
PLENARY SPEAKER BIOGRAPHIES

Rob Coster is the National Programme of Care Manager for the Blood and Infection Programme of care board and recently appointed as the Lead Commissioner for the HIV Clinical reference Group. Previously he worked with the BMT and Specialised Immunology and Allergy CRGS. Prior to joining NHS England, Rob worked in various operational, commissioning and nursing roles including HIV nursing in the late 90’s in the UK and Australia.

Dr Ian Gabriel is the Lead Clinician for haematological cancers at Chelsea and Westminster. He qualified in medicine from St Marys Hospital Medical School - Imperial College in 1999 and completed his specialist training in haematology in London. He holds a joint position with Imperial College NHS Trust (Hammersmith Hospital) where he is a consultant in haemato-oncology and stem cell transplantation. The haematology cancer service treats patients with complications of their cancer diagnosis, complications of their cancer treatment or those with an acute presentation of haematological cancer. Dr Gabriel has clinics in general haematology and also runs a clinic for patients with haematological complications of HIV disease and its treatment. His research interests are in stem cell transplant immunology, natural killer cell biology and HIV related haematology. He is the author of peer reviewed publications in lymphoma, myeloma, leukaemia and stem cell transplantation in addition to a number of book chapters.

Professor David Dockrell is a graduate of Trinity College Dublin and completed postgraduate training in the USA. He is professor of infection medicine at the University of Edinburgh. His clinical interests include opportunistic and lung infections in HIV, as well as non-infectious complications of HIV. Research interests have focused on the role of macrophages in the pathogenesis of HIV and other infectious diseases, in particular lung infections. He is a former Wellcome Trust senior clinical fellow and former co-director of the Florey Institute for Host-Pathogen Interactions, University of Sheffield and is a co-chair of the BHIVA guidelines on the management of opportunistic infections writing group.

Ms Ceri Dunstan is the policy and campaigns officer for Wales with the Terrence Higgins Trust.

Dr Nadia Ekong is a specialist registrar in sexual health and HIV medicine at Leeds Teaching Hospital. She is interested in women’s health, HIV prevention, and promoting sexual health awareness and access in ethnic minority communities. She completed research looking at recreational drug use and its association with sexual behaviours and STIs. She is the trainee representative at Leeds GUM speciality training committee.

Ms Natalie Gamble is a family lawyer who specialises in working with LGBT parents and families through assisted reproduction. She is the co-founder of NGA Law (the UK’s first fertility law firm) and Brilliant Beginnings (one of the UK’s three non-profit surrogacy agencies). A prominent campaigner for progressive law reform recognising modern families, she has been named in the Independent on Sunday’s Pink List as one of the 100 most influential gay people in the UK and nominated for Stonewall’s Hero of the Year Award. She is a regular voice on the BBC Radio 4 Today programme and on Woman’s Hour.

Dr Alberto Garcia-Basteiro currently coordinates the TB research unit at the Centro de Investigação em Saúde de Manhiça (CISM), Mozambique. He was trained as a physician at the University of Santiago de Compostela, Spain, and completed a residency on preventative medicine and public health at the Hospital Clinic, Barcelona and a master’s degree in epidemiology at the London School of Hygiene and Tropical Medicine. Since June 2012, he is affiliated with the Barcelona Institute for Global Health. His research on TB at CISM involves several large observational studies and clinical trials that contribute to the development of new tools to fight TB, in particular new diagnostic evaluations and drug clinical trials.

Professor Richard Harding is Herbert Dunhill Professor of Palliative Care and Rehabilitation at King’s College London. His research focuses on person-centred care and outcome measurement. He leads the development of the UK HIV patient-reported outcome measure and has a global programme of research to measure and improve patient outcomes from diagnosis to end of life.
PLENARY SPEAKER BIOGRAPHIES

Dr Paul Holmes is a consultant neurologist at Guy’s and St Thomas’ Hospitals. He completed his undergraduate training in South Africa and neurology training in London and was appointed to GSTT in 2003. He co-developed and runs the neurovascular clinic, a rapid response service for treatment of TIA, providing guidance on surgical and endovascular intervention. He set up the service for thrombolysis for acute stroke to deliver innovative, high-quality care for central/SE London. He provides a liaison service for the management of complex neurological problems on ITU and HDU, and a neurological consultation service to the departments of oncology, renal medicine, orthopaedics, haematology and vascular surgery. He has also set up a joint sickle cell disease/stroke clinic with haematology and leads in the neurology of HIV infection at Guy’s and St Thomas’ Hospitals.

Dr Ewan Hutchison graduated from Aberdeen University in 1992, completed general practice vocational training, gained a private pilot’s licence and worked for the Royal Flying Doctor Service in Australia. He undertook specialty training in occupational medicine and worked for Rolls-Royce before joining the Civil Aviation Authority in 2005. He is an educational supervisor for doctors in specialty training in aviation and space medicine, has worked with the International Civil Aviation Organization developing aviation medicine capability in East Africa and contributes to aviation medicine texts as author and editor.

Dr Ranjababu Kulasegaram (Babu) is a consultant in HIV/GU medicine at St Thomas’ Hospital and leads the HIV Treatment Advice Clinic, with special interests in HIV/hepatitis, haemophilia/HIV infection, HIV/neurocognitive function and HIV inpatient management. He is committed to enhancing BHIVA’s educational activities through his involvement as a course director for the BHIVA general medicine course, his contributions as one of the leads for the diploma in HIV medicine Revision course, and as a current member of the BHIVA Hepatitis Expert Advisory Group. He is an examiner for the diploma in HIV medicine, past Chair of the BHIVA Hepatitis Society and also served as vice chair of the BHIVA Education and Scientific subcommittee.

Dr Shimu Khamlichi is a clinical psychologist who works at the Ian Charleson Day Centre at the Royal Free Hospital, offering psychological support to people living with HIV. As part of a multidisciplinary team, she offers psychological assessment and intervention and provides specialist interventions to increase treatment adherence, reduce risk-taking behaviour and prevent HIV transmission. Additionally Dr Khamlichi conducts neurocognitive assessments and interventions for the management of neurocognitive deficits.

Professor Saye Khoo is professor at the Institute of Translational Medicine, University of Liverpool. He is consultant physician in infectious diseases at the Royal Liverpool University Hospital, and Chairs the Mersey, Cheshire and North Wales HIV Network. He also leads an active research programme in therapeutics of HIV, tuberculosis and hepatitis C. The primary research focus is on good prescribing and personalised treatment: this includes treatment optimisation in special populations (e.g. very young children, pregnant women, liver and kidney impairment), sterilisation of HIV within tissue compartments, drug interactions and HIV prevention. A comprehensive range of research tools are utilised, combining mass spectrometry, molecular characterisation and mathematical modelling (population PK and physiologically-based PK modelling). This research is funded by UNITAID, the Wellcome Trust, the Medical Research Council, the US National Institute of Health, NIHR, EPSRC, EDCTP and the pharmaceutical industry.

Dr Caroline Le Roy is a Research Associate at the department of Twin Research of King’s College London. Her work focuses on studying the host-gut microbiome metabolic crosstalk in health and disease as well as the gut microbiome in antibiotic resistance spread.

Dr Marc Lipman is a clinical academic based at the Royal Free London NHS Foundation Trust and University College London. He is a consultant in HIV and respiratory medicine, and director of UCL-TB, UCL’s cross-disciplinary TB research group. His interests include HIV-related respiratory disease, and mycobacterial infection.

Dr Douglas Macdonald graduated in 2001 with honours and distinctions in medical sciences and clinical medicine from the University of Southampton. He trained as a junior doctor on the Hammersmith rotation and King’s College Hospital liver transplant unit before working as an Imperial College research fellow in infectious diseases in Lima, Peru. He returned to London for specialist registrar training in gastroenterology and hepatology based at the Imperial College Hospital NHS Trust. He was awarded an MRC clinical research fellow ship in 2009 and completed a PhD in virology and immunology at University College London followed by a Bogue fellowship at Yale University in 2012. He has been a consultant hepatologist at the Royal Free Hospital and honorary senior lecturer at UCL since 2014, coordinating the introduction of new oral antiviral agents for hepatitis C. He leads the North Central London Hepatitis C Operational Delivery Network and is the regional chair for London.
PLENARY SPEAKER BIOGRAPHIES

Dr Ula Mahadeva is a consultant histopathologist at Guy’s and St Thomas’ NHS Foundation Trust where her areas of subspecialisation are gastrointestinal histopathology, gynaecological and non-gynaecological cytopathology, consented and maternal death autopsies, and infectious disease histopathology. She is known within the department and region for her enthusiasm for teaching and training, including helping trainees with preparation for the FRCPath examination, and is an RCPath examiner.

Dr Kelly O’Brien is a Canada Research Chair in episodic disability and rehabilitation and an associate professor in the Department of Physical Therapy, Institute of Health Policy, Management and Evaluation (IHPME) and Rehabilitation Sciences Institute (RSI) at the University of Toronto. Her research focuses on the episodic nature of disability experienced by adults ageing with HIV and determining the effectiveness of exercise interventions to improve their health outcomes. She co-led the formation of the Canada–United Kingdom (now International) HIV and Rehabilitation Research Collaborative, comprising over 80 researchers, clinicians, people living with HIV, community organisation representatives, and policy stakeholders with an interest in advancing HIV and rehabilitation research.

Dr Mary Poulton is a consultant in GUM/HIV and GUM specialty training Lead at King’s College Hospital (KCH). She also has a wider role of risk and governance Lead for post-acute and planned medicine at KCH. She has a particular interest in medical ethics and has a master’s degree in medical ethics and law from Keele University, previously having spent 4 years as KCH Caldicott Guardian. She was chair of the BASHH Information Group 2008–2012 and has been involved in various policy and guidance development projects relating to confidentiality and criminalisation of HIV transmission on behalf of BHIVA and BASHH.

Dr Robert Pralat is Leverhulme Early Career Fellow in the Department of Sociology, University of Cambridge. He is Chief Investigator of the Men’s Attitudes to Intimate Life (MAIL) study, funded by BHIVA and the Wellcome Trust, whose key aim is to explore views about parenthood and childfree living among HIV-positive gay and bisexual men. His research includes studies of generational changes in LGBTQ communities and, more recently, moral judgments about public funding of healthcare.

Ms Juliet Reid is the CEO and founder member of the Centre for All Families Positive Health (CAFPH) and has been a very vocal HIV advocate for many years. She has worked in the HIV sector since 1990 starting at the Terrence Higgins Trust as a volunteer, then working for Positively Women as a client services and housing worker. She has worked for Camden, Harringey and Luton PCTs as a health promotion specialist and an HIV/TB community awareness coordinator. Juliet is a specialist self-management trainer, treatment advocate and an immigration advisor. She has also worked as part of the Child Protection team and Traveller Education Support Service in Luton and has been a board member of different organisations, and worked in an advisory capacity for other small organisations. Juliet has participated in many HIV conferences local, national and international and is also involved in HIV work in Uganda supporting local initiatives in an advisory capacity to improve and develop services and models of good practice. She is currently working with a rural community hospital (Rugyeyo Community Hospital) helping to improve their HIV service, infrastructure and training for community outreach workers.

Professor Alison Rodger is professor of infectious diseases at University College London and a consultant in infectious diseases/HIV at the Royal Free London NHS Foundation Trust. She has been a co-author on several BHIVA guidelines including hepatitis co-infection, immunisations and post-exposure prophylaxis after sexual exposure (PEPSE) and co-chaired the BHIVA/BASHH guidelines on pre-exposure prophylaxis (PrEP) (2018). She is lead author on the PARTNER HIV transmission study and is PI on the PANTHEON NIHR programme grant looking at cost-effectiveness of HIV prevention and testing strategies, including HIV self-testing, among gay men.

Professor Caroline Sabin is professor of medical statistics and epidemiology at University College London (UCL) and is Director of the National Institutes for Health Research (NIHR), Health Protection Research Unit in Blood Borne and Sexually Transmitted Infections, a partnership between UCL, Public Health England (PHE) and the London School of Hygiene and Tropical Medicine. Caroline has worked for many years on the analysis of large observational HIV databases, with a particular interest in raising awareness of the biases inherent in these databases. She is the principal investigator on the UK CHIC study, the principal statistician on the D:A:D study, co-principal investigator on the POPPY study and has worked with many other research groups in the UK and elsewhere.
Mr Anthony Smith has recently begun his training to become a commercial airline pilot after successfully campaigning to change the regulations that had previously prohibited people living with HIV from entering the profession in the UK. He continues to work with a number of individuals and charities, seeking to establish a community-led, global activist group to challenge the regulations and restrictions that continue to adversely affect flight crew living with HIV in the UK, Europe and around the world.

Dr Claire Thorne is an associate professor in infectious disease epidemiology at the University College London Great Ormond Street Institute of Child Health. Her research has focused on the epidemiology of viral infections with respect to maternal and child health, with a particular emphasis on HIV, viral hepatitis and zika virus. Claire leads the UK and Ireland National Study of HIV in Pregnancy and Childhood and hepatitis B and C surveillance and cohort studies in the UK and Ukraine, and co-leads the European Pregnancy and Paediatric HIV Cohort Collaboration and PENTAHep (an international paediatric HCV clinical network).

Mr George Valiotis is the CEO of HIV Scotland, the national HIV policy organisation for Scotland. He is a member of the HIV-Anti Stigma Consortium, Scotland’s PrEP Coordination Group, and chairs the PrEP Education and Awareness Group. George has worked in HIV policy and capacity building across Europe and Australasia and brings experience from a broader range of areas, including diabetes, family mediation, and domestic violence.

Laura Waters is a consultant at the Mortimer Market Centre in London where she is HIV and Hepatitis Service Lead and principal investigator for several antiretroviral trials. She was Vice Chair of the 2015 BHIVA guidelines on the treatment of HIV-1-positive adults with ART and now chairs this group. She is Chair of the BHIVA Conferences Subcommittee and previous Chair of the BASHH HIV Special Interest Group. She is BASHH representative on the HIV CRG, Vice Chair HIV London leads group and a THT trustee.

Professor Janneke van de Wijgert is a professor in infection and global health at the Julius Center, University Medical Center Utrecht, the Netherlands, and the Institute of Infection and Global Health, University of Liverpool, UK. The current focus of her research is the role of the human microbiome in reproductive and neonatal health and in chronic infections and inflammatory conditions.

Professor Alan Winston is a professor of HIV and genitourinary medicine at Imperial College and consultant physician at St Mary’s Hospital, London. He has an MD in antiretroviral clinical pharmacology and his research focuses on non-infectious comorbidities associated with HIV-disease in the modern antiretroviral era, with a strong focus on central nervous system complications.
FORTHCOMING EVENTS AND MAJOR SPONSORS 2018

FORTHCOMING EVENTS

BHIVA General Medicine Course
Friday 16 November 2018
NVCO, London
Register at www.bhiva.org

BHIVA World AIDS Day
Celebrating our Communities: Art, History and Politics of HIV
Friday 30 November 2018
Central London Venue
Register at www.bhiva.org

BHIVA ‘Best of CROI’ Feedback 2019
Monday 18 March 2019, London
Tuesday 19 March 2019, Newcastle
Wednesday 20 March 2019, Haydock
Thursday 21 March 2019, Edinburgh
Tuesday 26 March 2019, Birmingham
Thursday 28 March 2019, Cardiff
All dates are provisional and subject to confirmation

25th Annual Conference of the British HIV Association (BHIVA)
3–5 April 2019
Bournemouth International Centre (BIC)

BHIVA Autumn Conference
3–4 October 2019
QEII Centre, London

BHIVA MAJOR SPONSORS 2018

Gilead Sciences Ltd
280 High Holborn
London
WC1V 7EE

Janssen
50–100 Holmers Farm Way
High Wycombe
Buckinghamshire HP12 4DP

MSD Ltd
Hertford Road
Hoddesdon
Hertfordshire EN11 9BU

ViiV Healthcare UK Ltd
Stockley Park West
Uxbridge
Middlesex UB11 1BT

BHIVA are grateful to their sponsors and exhibitors for their continued support. The funds provided are used solely for the educational content of the conference and are not allocated to the conference social events. Sponsors and Exhibitors have no involvement in the educational content of the BHIVA plenary programme or organisation of the conference.

For further information please contact:

BHIVA Conference Organisers
Mediscript Ltd
1 Mountview Court, 310 Friern Barnet Lane, London N20 0LD
Tel: 020 8369 5380 Fax: 020 8446 9194
Email: bhiva@bhiva.org Web: www.bhiva.org

Download the BHVA Conferences App

Final Programme
TIMES ARE CHANGING

In the management of HIV,
Are your treatment decisions changing with them?
Now is the time for a 2-drug regimen for your suppressed patients.*

* JULUCA ▼ is indicated for the treatment of HIV-1 infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen for at least 6 months with no history of virological failure and no known or suspected resistance to any NNRTI or INI.

Prescribing Information

Juluca ▼ dolutegravir 50mg/rilpivirine 25mg tablets
See Summary of Product Characteristics (SmPC) before prescribing
Indication: Indication: HIV-1 in virologically suppressed adults (HIV-1 RNA <50 copies/mL) on stable ART for at least 6 months with no history of virological failure and no known resistance to any NNRTI or INI.
Dosing: Adults (over 18 years): one tablet once daily with food.
Elderly: Limited data in 65+ yrs. Caution in severe hepatic or renal impairment. Contraindications: Hyper-sensitivity to any ingredient. Co-administration with dofetilide, carbamazepine, oxcarbazepine, phenobarbital, phenytoin, rifampicin, rifapentine, proton pump inhibitors, systemic dexamethasone (excluding single dose) or St John’s Wort.
Warnings/precautions: Risk of hypersensitivity reactions.
Discontinue Juluca immediately if suspected. Risks of prolongation of QTc interval, osteonecrosis, opportunistic infections. Monitor LFTs in Hepatitis B/C co-infection and ensure effective Hepatitis B therapy.
Small rise in serum creatinine in first 4 weeks of treatment, not considered clinically relevant. Do not co-administer with other antiretrovirals (except in case of co-administration of rifabutin, when an extra dose of rilpivirine 25mg should be used). Use with antacids or once-daily H2-receptor antagonists requires dosage separation.
Calcium, iron or multivitamins should be taken at the same time as Juluca with food, otherwise dosage separation recommended. Caution with metformin: monitor renal function and consider metformin dose adjustment to minimise risk of lactic acidosis.

Adverse events should be reported. For the UK, reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221441.

JULUCA is owned by or licensed to the ViiV Healthcare group of companies.
©2018 ViiV Healthcare group of companies or its licensor.

Date of preparation: August 2018 UK/DTGRPV/0058/18(1)